Upsher-Smith announced the launch of Topiramate Extended-Release Capsules, the generic version of its recently approved Qudexy XR (topiramate) extended-release capsules. Topiramate was approved in March 2014 as initial monotherapy in patients ≥10 years old with partial-onset seizures or primary generalized tonic-clonic seizures, and as adjunctive therapy in patients ≥2 years old with partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.
Topiramate Extended-Release Capsules are available as 25mg, 50mg, 100mg, 150mg, and 200mg dosage strengths in 500-count bottles.
For more information call (800) 654-2299 or visit Upsher-Smith.com.